Syon Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Syon Capital’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$333K	Sell	1,055 -12	-1%	-$2.83K	0.01%	762
2026 Q1	$213K	Buy	+1,067	New	+$211K	0.01%	862

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Syon Capital's LGND Position: Q2 2026 in Review

Syon Capital reduced its Ligand Pharmaceuticals (LGND) stake by 1.1% in Q2 2026, selling an estimated $2.83K and leaving 1,055 shares worth $333K. The position accounts for 0.01% of the portfolio, ranked #762.

Syon Capital first reported a position in LGND in Q1 2026 and has held it in 2 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Syon Capital held 1,055 shares of Ligand Pharmaceuticals worth $333K as of Q2 2026.
Syon Capital sold 12 Ligand Pharmaceuticals shares in Q2 2026, an estimated $2.83K.
Ligand Pharmaceuticals made up 0.01% of Syon Capital's portfolio in Q2 2026, its #762 holding.
Syon Capital first reported a position in Ligand Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Syon Capital's 13F filing for Q2 2026, filed 14 Aug 2026.